BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2005
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 12/16 cls
Actelion (SWX:ATLN) ING Bank Vontobel Sally Bennett Markus Metzger Downgrade Upgrade Hold (from buy) Market outperform (from market perform) -13% CHF 110
Bennett reiterated her CHF123.5 target but lowered her rating after ambrisentan from Myogen (MYOG) met the primary endpoint in the Phase III ARIES-2 trial to treat pulmonary arterial hypertension (PAH) (see "Walking Past the Competition," A21). She believes ambrisentan could displace ATLN's PAH drug Tracleer bosentan as market leader in FY08. Metzger said in a worse-case scenario, ATLN has an upside potential of 25% given the "exaggerated" price drop following MYOG's ambrisentan data. He believes ambrisentan will not compete with Tracleer until 2Q07.
Alnylam (ALNY) Banc of America David Witzke New Buy 1% $13.78
Witzke set an $18 target and FY05 and FY06 revenue estimates of $7.2M and $14.6M. He believes...

Read the full 869 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >